Step 1 of 2
Although evidence indicates that common pathophysiological factors contribute to obesity, metabolic dysfunction–associated steatotic liver disease (MASLD), and increased cardiovascular risk, MASLD and its more serious form, metabolic dysfunction–associated steatohepatitis (MASH), are often underrecognized and undertreated in the context of comprehensive, integrated cardiometabolic care. This downloadable slideset provides expert perspectives on the pathophysiology connecting obesity, liver health, and cardiovascular risk; current recommendations for identifying and assessing patients at risk for developing hepatic fibrosis; and current insights regarding available therapies for MASLD/MASH. The slides also explore emerging investigational agents and introduce strategies for incorporating MASLD/MASH into multidisciplinary cardiometabolic care.